British Patient Capital operates a £375m programme called Future Fund: Breakthrough, co-investing with private sector investors in R&D-intensive UK companies.
The financing round was co-led by Tencent and Flerie Invest to support Phase 1b clinical studies and pipeline expansion.
"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."
The Series B round was led by New Science Ventures to support international growth and manufacturing expansion.
"Our increasing desire for continually improving electronic device performance paired with the absolute necessity to reduce our power requirements, and hence carbon footprints, demands new technology solutions – next generation materials will be at the heart of this. At Paragraf we are proud to be leading the way, bringing the first 2D material, graphene, into the electronic product supply chain, through our first products, allowing its transformational, game changing properties and benefits to be harnessed."
Nyca Partners led the Series C round, which values the business at over $1bn and includes backing from several major global banks.
"We are delighted to have earned the support of our new and existing investors as we continue to move the world’s leading banks into the cloud. We set out to eradicate legacy technology from the industry and ensure that all banks deployed on Vault can succeed and deliver on their ambitions. These new funds will accelerate the delivery of Vault into banks around the world who wish to implement their future vision of financial services."
The financing round was backed by Tencent, British Patient Capital, CMB International, Mayfair Equity Partners, and IP Group.
"The metaverse concept is not new to Ultraleap. It has always been our mission to remove boundaries between physical and digital worlds. The pandemic has accelerated the rise of the term as more people now understand the power of enhancing the physical world with digital elements."
The Series B round was led by Lakestar with backing from institutional investors and venture funds to support team growth and product expansion.
"accuRx’s product has reinvigorated communication with our patients, enabling a better relationship between GPs and patients, which has ultimately led to better care provision. Our patients now have the confidence that they’re getting speedy and accurate responses from our team, and the use of regular Florey questionnaires to gather more information from our patients has been transformative for clinical record keeping and the care we provide. We’re thrilled that accuRx has received funding which will enable it to expand its primary care product set, some of which we’re trialling at the moment. We’re also excited about accuRx’s progress into secondary care as better interaction between primary and secondary care is a huge step forward for safer and more effective patient care."
